Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination

Philip C.S. De Whalley, Matthew D. Snape, Emma Plested, Ben Thompson, Elizabeth Nuthall, Omar Omar, Ray Borrow, Andrew J. Pollard

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objectives To determine long-term seroprotection after serogroup C meningococcal (MenC) vaccination at the age of 9-12 years, with or without booster vaccination at the age of 13-15 years. Design Observational cohort study; follow-on from randomised study. Setting Participants were recruited from English secondary schools (in Oxfordshire and Buckinghamshire). Participants and interventions Participants were primed with MenC CRM-glycoconjugate vaccine at the age of 9-12 years in the UK routine immunisation campaign. In previous studies they were randomised at 13 to 15 years of age to receive a booster dose of MenC-CRM glycoconjugate vaccine (CRM-group) or bivalent meningococcal serogroup A/C polysaccharide vaccine (PS-group), or they received no additional doses of MenC vaccine (control group). In this follow-on study, a blood sample was obtained 11 years after primary immunisation. Of 531 individuals eligible to participate, 134 were enrolled, and 124 were included in the analysis. Main outcome measures MenC serum bactericidal antibody (SBA) geometric mean titre; proportion of participants with SBA titre ≥8 ( putative protective threshold). Results Median ages at priming, boosting and blood sampling were 10.61, 14.42 and 22.11 years, respectively. Geometric mean titres for MenC SBA were: CRM group 1373 (95% CI 954 to 1977); PS group 1024 (687 to 1526); and controls 284 (167 to 483). SBA titres =8 were present in 50/54 (92.6%) controls and 70/70 (100%) boosted individuals. Conclusions The planned introduction in the UK of an adolescent booster of MenC conjugate vaccine in 2013 is likely to provide sustained protection against MenC disease.

Original languageEnglish
Pages (from-to)686-691
Number of pages6
JournalArchives of Disease in Childhood
Volume98
Issue number9
DOIs
Publication statusPublished - 1 Sep 2013
Externally publishedYes

Fingerprint

Vaccination
Meningococcal Vaccines
Glycoconjugates
Vaccines
Antibodies
Serum
Immunization
Conjugate Vaccines
Observational Studies
Polysaccharides
Cohort Studies
Outcome Assessment (Health Care)
Control Groups
Serogroup

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

De Whalley, P. C. S., Snape, M. D., Plested, E., Thompson, B., Nuthall, E., Omar, O., ... Pollard, A. J. (2013). Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination. Archives of Disease in Childhood, 98(9), 686-691. https://doi.org/10.1136/archdischild-2013-303893

Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination. / De Whalley, Philip C.S.; Snape, Matthew D.; Plested, Emma; Thompson, Ben; Nuthall, Elizabeth; Omar, Omar; Borrow, Ray; Pollard, Andrew J.

In: Archives of Disease in Childhood, Vol. 98, No. 9, 01.09.2013, p. 686-691.

Research output: Contribution to journalArticle

De Whalley, PCS, Snape, MD, Plested, E, Thompson, B, Nuthall, E, Omar, O, Borrow, R & Pollard, AJ 2013, 'Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination', Archives of Disease in Childhood, vol. 98, no. 9, pp. 686-691. https://doi.org/10.1136/archdischild-2013-303893
De Whalley, Philip C.S. ; Snape, Matthew D. ; Plested, Emma ; Thompson, Ben ; Nuthall, Elizabeth ; Omar, Omar ; Borrow, Ray ; Pollard, Andrew J. / Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination. In: Archives of Disease in Childhood. 2013 ; Vol. 98, No. 9. pp. 686-691.
@article{6d97e2dee4c14eaeb61dea888defccb4,
title = "Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination",
abstract = "Objectives To determine long-term seroprotection after serogroup C meningococcal (MenC) vaccination at the age of 9-12 years, with or without booster vaccination at the age of 13-15 years. Design Observational cohort study; follow-on from randomised study. Setting Participants were recruited from English secondary schools (in Oxfordshire and Buckinghamshire). Participants and interventions Participants were primed with MenC CRM-glycoconjugate vaccine at the age of 9-12 years in the UK routine immunisation campaign. In previous studies they were randomised at 13 to 15 years of age to receive a booster dose of MenC-CRM glycoconjugate vaccine (CRM-group) or bivalent meningococcal serogroup A/C polysaccharide vaccine (PS-group), or they received no additional doses of MenC vaccine (control group). In this follow-on study, a blood sample was obtained 11 years after primary immunisation. Of 531 individuals eligible to participate, 134 were enrolled, and 124 were included in the analysis. Main outcome measures MenC serum bactericidal antibody (SBA) geometric mean titre; proportion of participants with SBA titre ≥8 ( putative protective threshold). Results Median ages at priming, boosting and blood sampling were 10.61, 14.42 and 22.11 years, respectively. Geometric mean titres for MenC SBA were: CRM group 1373 (95{\%} CI 954 to 1977); PS group 1024 (687 to 1526); and controls 284 (167 to 483). SBA titres =8 were present in 50/54 (92.6{\%}) controls and 70/70 (100{\%}) boosted individuals. Conclusions The planned introduction in the UK of an adolescent booster of MenC conjugate vaccine in 2013 is likely to provide sustained protection against MenC disease.",
author = "{De Whalley}, {Philip C.S.} and Snape, {Matthew D.} and Emma Plested and Ben Thompson and Elizabeth Nuthall and Omar Omar and Ray Borrow and Pollard, {Andrew J.}",
year = "2013",
month = "9",
day = "1",
doi = "10.1136/archdischild-2013-303893",
language = "English",
volume = "98",
pages = "686--691",
journal = "Archives of Disease in Childhood",
issn = "0003-9888",
publisher = "BMJ Publishing Group",
number = "9",

}

TY - JOUR

T1 - Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination

AU - De Whalley, Philip C.S.

AU - Snape, Matthew D.

AU - Plested, Emma

AU - Thompson, Ben

AU - Nuthall, Elizabeth

AU - Omar, Omar

AU - Borrow, Ray

AU - Pollard, Andrew J.

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Objectives To determine long-term seroprotection after serogroup C meningococcal (MenC) vaccination at the age of 9-12 years, with or without booster vaccination at the age of 13-15 years. Design Observational cohort study; follow-on from randomised study. Setting Participants were recruited from English secondary schools (in Oxfordshire and Buckinghamshire). Participants and interventions Participants were primed with MenC CRM-glycoconjugate vaccine at the age of 9-12 years in the UK routine immunisation campaign. In previous studies they were randomised at 13 to 15 years of age to receive a booster dose of MenC-CRM glycoconjugate vaccine (CRM-group) or bivalent meningococcal serogroup A/C polysaccharide vaccine (PS-group), or they received no additional doses of MenC vaccine (control group). In this follow-on study, a blood sample was obtained 11 years after primary immunisation. Of 531 individuals eligible to participate, 134 were enrolled, and 124 were included in the analysis. Main outcome measures MenC serum bactericidal antibody (SBA) geometric mean titre; proportion of participants with SBA titre ≥8 ( putative protective threshold). Results Median ages at priming, boosting and blood sampling were 10.61, 14.42 and 22.11 years, respectively. Geometric mean titres for MenC SBA were: CRM group 1373 (95% CI 954 to 1977); PS group 1024 (687 to 1526); and controls 284 (167 to 483). SBA titres =8 were present in 50/54 (92.6%) controls and 70/70 (100%) boosted individuals. Conclusions The planned introduction in the UK of an adolescent booster of MenC conjugate vaccine in 2013 is likely to provide sustained protection against MenC disease.

AB - Objectives To determine long-term seroprotection after serogroup C meningococcal (MenC) vaccination at the age of 9-12 years, with or without booster vaccination at the age of 13-15 years. Design Observational cohort study; follow-on from randomised study. Setting Participants were recruited from English secondary schools (in Oxfordshire and Buckinghamshire). Participants and interventions Participants were primed with MenC CRM-glycoconjugate vaccine at the age of 9-12 years in the UK routine immunisation campaign. In previous studies they were randomised at 13 to 15 years of age to receive a booster dose of MenC-CRM glycoconjugate vaccine (CRM-group) or bivalent meningococcal serogroup A/C polysaccharide vaccine (PS-group), or they received no additional doses of MenC vaccine (control group). In this follow-on study, a blood sample was obtained 11 years after primary immunisation. Of 531 individuals eligible to participate, 134 were enrolled, and 124 were included in the analysis. Main outcome measures MenC serum bactericidal antibody (SBA) geometric mean titre; proportion of participants with SBA titre ≥8 ( putative protective threshold). Results Median ages at priming, boosting and blood sampling were 10.61, 14.42 and 22.11 years, respectively. Geometric mean titres for MenC SBA were: CRM group 1373 (95% CI 954 to 1977); PS group 1024 (687 to 1526); and controls 284 (167 to 483). SBA titres =8 were present in 50/54 (92.6%) controls and 70/70 (100%) boosted individuals. Conclusions The planned introduction in the UK of an adolescent booster of MenC conjugate vaccine in 2013 is likely to provide sustained protection against MenC disease.

UR - http://www.scopus.com/inward/record.url?scp=84883133746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883133746&partnerID=8YFLogxK

U2 - 10.1136/archdischild-2013-303893

DO - 10.1136/archdischild-2013-303893

M3 - Article

VL - 98

SP - 686

EP - 691

JO - Archives of Disease in Childhood

JF - Archives of Disease in Childhood

SN - 0003-9888

IS - 9

ER -